We are international
Donate
• health professionals TEXT SIZE   
Bringing the Experts to You



XIIth International Myeloma Workshop, Day 4, March 1, 2009

  • 08:15-10:15 Pro and Con Session
  • 10:30-12:30 Phase II Studies
  • 13:30-15:00 Plenary Session
  • 15:30-17:30 Future Perspectives/Closing Ceremony
Complete Program Listing

2009 IMW Sunday Sessions

Pro and Con Session
Simultaneous use of Novel Agents in Induction Therapy
XIIth International Myeloma Workshop in Washington, DC
Morie Gertz, M.D.
Mayo Clinic
Rochester, Minnesota

Sequential use of Novel agents in Induction Therapy
XIIth International Myeloma Workshop in Washington, DC
Joan Bladé, M.D.
Hospital Clinic
Barcelona, Spain

Simultaneous vs. Sequential Use of Novel Agents in Induction Therapy
Rebuttal by Drs. Gertz and Bladé followed by Q & A Period

Therapy Should be Based on Risk Satisfaction - Favor
XIIth International Myeloma Workshop in Washington, DC
Angela Dispenzieri, M.D.
Mayo Clinic
Rochester, Minnesota

Therapy Should be Based on Risk Stratification - Against
XIIth International Myeloma Workshop in Washington, DC
Jesus San-Miguel, M.D.
University Hospital
Salamanca, Spain

Should Myeloma Therapy Be Based on Risk Stratification?
Rebuttal by Drs. Dispenzieri and San Miguel followed by Q & A Period

Is there a role for Allo Tx? - Favor
XIIth International Myeloma Workshop in Washington, DC
Jayesha Mehta, M.D.
Northwestern Medical School
Chicago, Illinois

Is there a role for Allo Tx? - Against
XIIth International Myeloma Workshop in Washington, DC
Jean Paul Fermand, M.D.
Hôpital Saint-Louis
Paris, France

Is There a Place for Allogeneic Transplantation in Myeloma in the Era of Novel Agents?
Rebuttal by Drs. Mehta and Fermand followed by Q & A Period

Phase II Studies
US/DFCI - New Agents
XIIth International Myeloma Workshop in Washington, DC
Kenneth Anderson. M.D. substituting for Paul Richardson, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Early Combination Studies - "New Combination Approaches for MM"
XIIth International Myeloma Workshop in Washington, DC
Antonio Palumbo, M.D.
Ospedale San Giovanni Battista
Torino, Italia

New Proteasome Inhibitors
XIIth International Myeloma Workshop in Washington, DC
Robert Orlowski, M.D.
MD Anderson Cancer Center
Houston, Texas

Novel Bone Targeting Agents in Myeloma
XIIth International Myeloma Workshop in Washington, DC
Noopur Raje, M.D.
Massachusetts General Hospital Cancer Center
Center for Multiple Myeloma
Boston, Massachusetts

New Imids
XIIth International Myeloma Workshop in Washington, DC
Martha Lacy, M.D.
Mayo Clinic
Rochester, Minnesota

Plenary Session
Lenalidomide Inhibits the Multiple Myeloma Cell-Survival Factor IRF4/MUM1
XIIth International Myeloma Workshop in Washington, DC
Antonia Lopez-Girona, M.D.
Celgene Corporation

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Marc Raab, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Whole Body MRI in Asymptomatic Plasma Cell Disease
XIIth International Myeloma Workshop in Washington, DC
Jens Hillengass, M.D.
University of Heidelberg
Heidelberg, Germany

Superiority of VTD Over TD Incorporated Into ASCT for Newly Diagnosed MM
XIIth International Myeloma Workshop in Washington, DC
Michele Cavo, M.D.
Istituto "Seragnoli"
Bologna, Italy